From: NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients
Patient identifier | Study | BMA time pointsa | NR2F1/AE1AE3 DIF analysis | Ki67/AE1AE3 DIF analysis | HR | HER2 | T status | N status | Time (months) from BMA to systemic relapse or BC death | Relapse status or BC death (if not recorded relapse) | Time (months) from BMA to last observation if no relapse | Comment | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. of DTCs | % NR2F1high DTCs | No. of DTCs | % Ki67+ DTCs | |||||||||||
20 | N | (BM1)-BM3 | 35 | 0 | 7 | 28.6 | pos | nd | 3 | 2 | 0.30 | Bone and visceral | ||
74 | S | (BM1-BM3)-BM4 | 3 | 0 | nd | nd | pos | neg | 1 | 1 | 1.09 | Bone | ||
5 | O | (BM1)/BM2 | 1000 | 0 | 1000 | 15.0 | pos | pos | 1 | 1 | 1.15 | Bone | ||
60 | S | (BM2)-BM3 | 1000 | 0b | 84 | 26,2 | pos | neg | 2 | 1 | 1.84 | Bone | ||
27 | N | (BM1)-BM2 | 5 | 0c | nd | nd | neg | nd | 3 | 0 | 5.69 | Visceral | ||
62 | S | BM2 | 40,000 | 0 | nd | nd | pos | neg | 2 | 0 | 5.79 | Bone and visceral | Chemo after BMA | |
4 | O | (BM1)-BM2 | 9 | 0 | 23 | 21.7 | pos | neg | 3 | 1 | 7.50 | Bone and visceral | ||
3 | O | BM1 | 11 | 0 | nd | nd | pos | neg | 2 | 1 | 11.22 | Visceral | ||
78 | S | (BM1)-BM2-(BM3) | 26 | 0 | 29 | 13.8 | pos | neg | 2 | 3 | 13.19 | Bone and visceral | Chemo after BMA | |
13 | O | BM1 | 79 | 0 | nd | Nd | neg | pos | 1 | 1 | 13.22 | Bone | Chemo after BMA | |
17 | N | BM3 | 5 | 0 | 4 | 25.0 | pos | nd | 3 | 1 | 17.57 | Bone and visceral | ||
34 | N | BM1-(BM2) | 2 | 0 | nd | nd | pos | neg | 3 | 1 | 47.43 | Visceral | Chemo after BMA | |
12 | O | BM2 | 16 | 0 | nd | nd | pos | neg | 2 | 1 | No relapse | 57.73 | ||
66 | S | BM1-(BM4) | 3 | 0 | nd | nd | pos | neg | 1 | 2 | No relapse | 87.50 | Chemo after BMA | |
11 | O | (BM1)-BM2 | 500 | 1.0 | 87 | 66.7 | neg | pos | 3 | 1 | 3.72 | BC death | ||
23 | N | BM3 | 50 | 10.0 | 16 | 12.5 | pos | pos | 3 | 0 | 13.55 | BC death | ||
35 | N | (BM1)-BM3 | 7 | 14.3 | 12 | 25.0 | pos | nd | 3 | 2 | N/A | d | Met. before BMA | |
48 | (BM1)-BM3 | 17 | 25.5 | 10 | 20.0 | pos | nd | 3 | 0 | 12.24 | Bone | |||
41 | N | BM3 | 111 | 30.6 | 82 | 17.1 | pos | nd | 4 | 1 | N/A | d | Met. before BMA | |
36 | N | (BM1)-BM3 | 6 | 50,0 | 4 | 50.0 | pos | nd | 3 | 1 | 25.33 | Bone | ||
84 | S | (BM1)-BM2 | 2 | 50.0 | nd | nd | pos | neg | 2 | 2 | No relapse | 55.53 | Chemo after BMA | |
9 | O | BM1 | 48 | 56.3 | nd | Nd | neg | neg | 2 | 1 | N/A | Boned | Met. at BMA | |
85 | S | (BM1)-BM2 | 106 | 56.6 | 70 | 10.0 | pos | neg | 2 | 2 | No relapse | 56.02 | Chemo after BMA | |
69 | S | (BM1)-BM2-(BM3) | 52 | 65.4 | 35 | 0 | pos | neg | 2 | 2 | 15.10 | Visceral | Chemo after BMA | |
6 | O | (BM1)-BM2 | 233 | 94.9 | 400 | 1.0 | neg | pos | 1 | 1 | N/A | Visceral | Met. before BMA | |
57 | S | (BM3)-BM4 | 6 | 100 | nd | nd | neg | nd | 2 | 0 | No relapse | 59.93 |